$659 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 108 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLLS | CELLECTIS S Asponsored ads | $10,693,000 | +8.1% | 339,367 | 0.0% | 1.62% | +39.8% | |
| AGN | ALLERGAN PLC | $10,097,000 | +2.9% | 60,000 | 0.0% | 1.53% | +33.1% | |
| ARRY | ARRAY BIOPHARMA INC | $6,610,000 | +27.5% | 405,000 | 0.0% | 1.00% | +65.1% | |
| PIRS | PIERIS PHARMACEUTICALS INC | $5,456,000 | -9.7% | 800,000 | 0.0% | 0.83% | +16.8% | |
| NERV | MINERVA NEUROSCIENCES INC | $4,844,000 | +3.3% | 775,000 | 0.0% | 0.74% | +33.6% | |
| RETA | REATA PHARMACEUTICALS INCcl a | $4,615,000 | -27.6% | 225,000 | 0.0% | 0.70% | -6.3% | |
| CTIC | CTI BIOPHARMA CORP | $3,251,000 | +45.5% | 833,633 | 0.0% | 0.49% | +88.5% | |
| BOLD | AUDENTES THERAPEUTICS INC | $2,855,000 | -3.8% | 95,000 | 0.0% | 0.43% | +24.4% | |
| ERYP | ERYTECH PHARMAsponsored adr | $2,520,000 | -4.6% | 120,000 | 0.0% | 0.38% | +23.5% | |
| RDCM | RADCOM LTD | $1,207,000 | -7.5% | 65,760 | 0.0% | 0.18% | +19.6% | |
| VTGN | VISTAGEN THERAPEUTICS INC | $1,157,000 | -16.4% | 1,247,251 | 0.0% | 0.18% | +8.6% | |
| VTVT | VTV THERAPEUTICS INCcl a | $1,146,000 | -32.3% | 281,679 | 0.0% | 0.17% | -12.6% | |
| AQXP | AQUINOX PHARMACEUTICALS INC | $1,064,000 | +19.8% | 75,535 | 0.0% | 0.16% | +55.8% | |
| TEVA PHARMACEUTICAL FIN LLCdbcv 0.250% 2/0 | $703,000 | -7.3% | 2,135 | 0.0% | 0.11% | +20.2% | ||
| UNH | UNITEDHEALTH GROUP INC | $428,000 | -2.9% | 2,000 | 0.0% | 0.06% | +25.0% | |
| WSO | WATSCO INC | $380,000 | +6.4% | 2,100 | 0.0% | 0.06% | +38.1% | |
| MHK | MOHAWK INDS INC | $255,000 | -15.8% | 1,100 | 0.0% | 0.04% | +8.3% | |
| ULTI | ULTIMATE SOFTWARE GROUP INC | $195,000 | +11.4% | 800 | 0.0% | 0.03% | +42.9% | |
| SEE | SEALED AIR CORP NEW | $193,000 | -13.1% | 4,500 | 0.0% | 0.03% | +11.5% | |
| XRAY | DENTSPLY SIRONA INC | $126,000 | -23.6% | 2,500 | 0.0% | 0.02% | 0.0% | |
| VSTO | VISTA OUTDOOR INC | $98,000 | +12.6% | 6,000 | 0.0% | 0.02% | +50.0% | |
| ATHX | ATHERSYS INC | $1,000 | 0.0% | 773 | 0.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.